Program
nerandomilast
Also written as “BI 1015550”, “Nerandomilast” and “Nerandomilast formulation 1”.
Its studies are mostly in Lung Diseases, Interstitial · Idiopathic Pulmonary Fibrosis · Myositis · Scleroderma, Systemic · Amyotrophic Lateral Sclerosis, led by 2 companies.
Drug pageNerandomilast: every studyAll 36 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Boehringer Ingelheimits history only | 347 open or running | phase 3since Apr 4, 2022 | May 7, 2012 | Apr 15, 2027phase 3 · NCT06806592 |
| Gipfel Life Sciencesits history only | 11 open or running | phase 3since Jan 2, 2026 | Jan 2, 2026 | Jun 30, 2027phase 3 · NCT07321860 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Not listed one by one: 19 earlier studies, May 7, 2012 to Oct 2, 2023.
- Aug 6, 2023Named nerandomilastINNProposed as its International Nonproprietary Name in WHO's List 129 · before, BI 1015550
- Nov 15, 2023Phase 1 study in HealthyBoehringer Ingelheim · NCT06139302 · 12 enrolled · Japan
- Jan 25, 2024Phase 3 study in Idiopathic Pulmonary FibrosisBoehringer Ingelheim · NCT06238622 · 1,666 enrolled · United States, Argentina, Australia and more
- Jan 29, 2024Phase 2 study in Idiopathic Pulmonary FibrosisBoehringer Ingelheim · NCT06241560 · 20 enrolled · United States, Georgia
- Apr 29, 2024Phase 1 study in HealthyBoehringer Ingelheim · NCT06393127 · 64 enrolled · Germany
- May 7, 20242 phase 1 studies in HealthyBoehringer Ingelheim · NCT06408870, NCT06415045
- Oct 1, 2024Phase 1 study in HealthyBoehringer Ingelheim · NCT06624072 · 15 enrolled · Germany
- Jan 28, 2025Phase 3 study in Lung Diseases, InterstitialBoehringer Ingelheim · NCT06806592 · 414 enrolled · United States, Australia, Austria and more
- Jul 22, 20252 phase 1 studies in HealthyBoehringer Ingelheim · NCT07081932, NCT07100964
- Sep 30, 2025Phase 3 study in Lung Diseases, InterstitialBoehringer Ingelheim · NCT07201922 · 80 planned · United States, Argentina, Australia and more
- Jan 2, 2026Gipfel Life Sciences’ first study: phase 3 study in Amyotrophic Lateral SclerosisNew to Gipfel Life SciencesGipfel Life Sciences · NCT07321860 · 60 planned
- Jan 23, 2026Phase 3 study in Fibrosing Interstitial Lung DiseaseBoehringer Ingelheim · NCT07366034 · 35 planned · United States, Argentina, Australia and more
- Mar 23, 2026Phase 3 study in Scleroderma, SystemicBoehringer Ingelheim · NCT07497087 · 448 planned · United States, Argentina, Australia and more
- Apr 15, 2026Phase 3 study in Lung Diseases, InterstitialBoehringer Ingelheim · NCT07540988 · 466 planned · United States, Argentina, Australia and more
- Aug 24, 2026Phase 3 study in MyositisBoehringer Ingelheim · NCT07789015 · 270 planned · United States, Argentina, Australia and more
Ahead
- Apr 15, 2027Primary completion: phase 3 study in Lung Diseases, InterstitialBoehringer Ingelheim · NCT06806592
- Apr 28, 2027Primary completion: phase 3 study in Idiopathic Pulmonary FibrosisBoehringer Ingelheim · NCT06238622
- Jun 30, 2027Primary completion: phase 3 study in Amyotrophic Lateral SclerosisGipfel Life Sciences · NCT07321860
- Dec 5, 2028Primary completion: phase 3 study in Lung Diseases, InterstitialBoehringer Ingelheim · NCT07540988
TargetBeta
“Meanwhile, nerandomilast, a selective PDE4B inhibitor, elevates intracellular cAMP in immune and glial cells, shifting pro-inflammatory signaling toward resolution and antagonizing secondary fibrotic and inflammatory cascades.”study text, by rule · the study
Other programs on PDE4B
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Roflumilastrule | AstraZeneca | phase 4 | 61 |
| apremilastrule | Amgen | phase 4 | 48 |
| ensifentrinerule | Merck | phase 3 | 17 |
| difamilastrule | Otsuka | phase 3 | 16 |
| tanimilastrule | Chiesi Farmaceutici | phase 3 | 15 |
Studies
All 35 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07789015Myositis · United States, Argentina, Australia and more | 3 | Not yet recruiting | Boehringer Ingelheim | Mar 21, 2030 | 270 |
| NCT07540988Lung Diseases, Interstitial · United States, Argentina, Australia and more | 3 | Recruiting | Boehringer Ingelheim | Dec 5, 2028 | 466 |
| NCT07497087Scleroderma, Systemic · United States, Argentina, Australia and more | 3 | Recruiting | Boehringer Ingelheim | Feb 26, 2030 | 448 |
| NCT07366034Fibrosing Interstitial Lung Disease · United States, Argentina, Australia and more | 3 | Recruiting | Boehringer Ingelheim | Apr 27, 2029 | 35 |
| NCT07321860Amyotrophic Lateral Sclerosis | 3 | Not yet recruiting | Gipfel Life Sciences | Jun 30, 2027 | 60 |
| NCT07201922Lung Diseases, Interstitial · United States, Argentina, Australia and more | 3 | Recruiting | Boehringer Ingelheim | May 14, 2029 | 80 |
| NCT07100964Healthy · Germany | 1 | Completed | Boehringer Ingelheim | Sep 20, 2025 | 16 |
| NCT07081932Healthy · Germany | 1 | Completed | Boehringer Ingelheim | Sep 27, 2025 | 16 |
| NCT06806592Lung Diseases, Interstitial · United States, Australia, Austria and more | 3 | Active, not recruiting | Boehringer Ingelheim | Apr 15, 2027 | 414 |
| NCT06624072Healthy · Germany | 1 | Completed | Boehringer Ingelheim | Nov 22, 2024 | 15 |
| NCT06415045Healthy · Germany | 1 | Completed | Boehringer Ingelheim | Jul 24, 2024 | 18 |
| NCT06408870Healthy · Germany | 1 | Completed | Boehringer Ingelheim | Aug 28, 2024 | 64 |
| NCT06393127Healthy · Germany | 1 | Completed | Boehringer Ingelheim | Sep 10, 2024 | 64 |
| NCT06241560Idiopathic Pulmonary Fibrosis · United States, Georgia | 2 | Completed | Boehringer Ingelheim | Aug 5, 2026 | 20 |
| NCT06238622Idiopathic Pulmonary Fibrosis · United States, Argentina, Australia and more | 3 | Active, not recruiting | Boehringer Ingelheim | Apr 28, 2027 | 1,666 |
| NCT06139302Healthy · Japan | 1 | Completed | Boehringer Ingelheim | Feb 7, 2024 | 12 |
| NCT06107036Healthy · United Kingdom | 1 | Completed | Boehringer Ingelheim | Jul 25, 2024 | 46 |
| NCT06070610Healthy · Germany | 1 | Completed | Boehringer Ingelheim | Dec 14, 2023 | 14 |
| NCT05718648Renal Insufficiency · Germany | 1 | Completed | Boehringer Ingelheim | Aug 15, 2023 | 26 |
| NCT05707403Healthy · Netherlands | 1 | Completed | Boehringer Ingelheim | Mar 28, 2023 | 8 |
| NCT05661344Hepatic Insufficiency · Germany | 1 | Completed | Boehringer Ingelheim | Sep 13, 2023 | 28 |
| NCT05633862Healthy · China | 1 | Completed | Boehringer Ingelheim | Mar 16, 2023 | 24 |
| NCT05550636Healthy · Germany | 1 | Completed | Boehringer Ingelheim | Dec 19, 2022 | 15 |
| NCT05428436Healthy · Germany | 1 | Completed | Boehringer Ingelheim | Sep 30, 2022 | 24 |
| NCT05321082Lung Diseases, Interstitial · United States, Argentina, Australia and more | 3 | Completed | Boehringer Ingelheim | Dec 18, 2024 | 1,178 |
| NCT05321069Idiopathic Pulmonary Fibrosis · United States, Argentina, Australia and more | 3 | Completed | Boehringer Ingelheim | Aug 16, 2024 | 1,177 |
| NCT04771286Healthy · Netherlands | 1 | Completed | Boehringer Ingelheim | May 17, 2021 | 6 |
| NCT04419506Idiopathic Pulmonary Fibrosis · United States, Argentina, Australia and more | 2 | Completed | Boehringer Ingelheim | Oct 6, 2021 | 147 |
| NCT03542344Healthy · Japan | 1 | Completed | Boehringer Ingelheim | Aug 24, 2018 | 16 |
| NCT03422068Idiopathic Pulmonary Fibrosis · Denmark, Finland, Germany and more | 1 | Completed | Boehringer Ingelheim | Jul 1, 2019 | 15 |
| NCT03403439Healthy · Germany | 1 | Completed | Boehringer Ingelheim | Jul 20, 2018 | 16 |
| NCT03302078Healthy · Germany | 1 | Completed | Boehringer Ingelheim | Dec 13, 2017 | 12 |
| NCT03230487Healthy · Germany | 1 | Completed | Boehringer Ingelheim | Jan 16, 2018 | 42 |
| NCT01835899Healthy · Germany | 1 | Completed | Boehringer Ingelheim | Jun 2013 | 24 |
| NCT01594515Healthy · Germany | 1 | Completed | Boehringer Ingelheim | Sep 2012 | 70 |
How it is read
Names in the registry
- “BI 1015550”, 27 entries
- “Nerandomilast”, 10 entries
- “Nerandomilast formulation 1”, 1 entry
- “Nerandomilast formulation 2”, 1 entry
- “Nerandomilast 18 mg - adult formulation”, 1 entry
Conditions, from the studies’ own filings
- Lung Diseases, Interstitial, 5 studies
- Idiopathic Pulmonary Fibrosis, 5 studies
- Myositis, 1 study
- Scleroderma, Systemic, 1 study
- Amyotrophic Lateral Sclerosis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.